This is when a doctor gives you a special kind of blood, called white blood cells, from someone else. These white blood cells help your body fight off infections. It's a way to boost your immune system if you need it.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
A white blood cell transfusion, known in hospitals as a granulocyte transfusion, gives a person neutrophils collected from a donor. Neutrophils are the white blood cells that lead the body's early defense against bacteria and fungi. When their count falls very low, a state called neutropenia, infections become much more likely and harder to control, even with strong antibiotics and antifungal medicines. The treatment is considered mainly for people whose neutrophils are very low because of a blood cancer such as leukemia, intensive chemotherapy or a stem cell transplant, and who have a serious bacterial or fungal infection that has not improved after one to two days of appropriate treatment. Doctors usually use an absolute neutrophil count below 500 cells per microliter of blood as the threshold for severe neutropenia. It is also occasionally used for rare inherited conditions in which neutrophils are present but do not work properly. Donated neutrophils survive only a short time, so the transfusion works as a temporary bridge: it is meant to help fight an infection until the person's own bone marrow starts making neutrophils again. For that reason it is generally not used when recovery of the marrow is not expected. It is always added to antibiotic or antifungal treatment, never a substitute for it. Growth factor medicines such as G-CSF (granulocyte colony-stimulating factor), which push the marrow to make more neutrophils, are a separate way to speed recovery.
Granulocyte transfusions are uncommon, and each dose is collected for one specific patient. The treating team arranges it with the hospital's transfusion medicine service and a blood center. The donor's blood type has to match the recipient's, because the product contains a substantial number of red blood cells. People who have never had cytomegalovirus (CMV), a common virus, should receive cells from donors who also test negative for it. To raise the number of neutrophils they can give, the donor usually takes a steroid medicine, dexamethasone, and sometimes an injection of G-CSF beforehand. The cells are then collected by apheresis, in which the donor's blood passes through a machine that separates out the white cells and returns the rest. Timing shapes everything about this treatment. Collected neutrophils begin to lose function within 6 to 8 hours and can be kept for no more than 24 hours, so they are given as soon as possible. Routine infection testing of donated blood takes 24 to 48 hours, which means the transfusion usually happens before the donor's test results are back. The team should explain how it manages that trade-off. For the person receiving the cells, preparation is similar to any transfusion: blood type and antibody testing and a working IV line. Some centers give a fever reducer (acetaminophen) and an antihistamine (diphenhydramine) beforehand to lessen reactions. If a stem cell transplant is planned, tell the team, because transfusions can affect it.
The cells arrive from the blood center already irradiated, meaning treated with radiation so that donor immune cells cannot attack the recipient's body. They are given through an IV (a thin tube in a vein) or a central line, in much the same way as a red cell or platelet transfusion. Nurses check temperature, blood pressure, breathing and oxygen levels throughout. Possible reactions include fever and chills, itching or hives, a drop in blood pressure and sudden difficulty breathing. Because a person with a serious infection may already have fever or breathing problems, the team watches closely to tell a reaction apart from the illness itself. Tell the nurse right away about chills, new shortness of breath, chest tightness, itching or suddenly feeling worse, during the transfusion or in the hours after it. If a reaction is suspected, the transfusion is stopped immediately and the blood bank investigates. Most people who receive this treatment get a series of transfusions rather than a single one.
There is no recovery period from the transfusion itself in the usual sense: the person is already in the hospital being treated for a serious infection. Afterward, the team follows fever, blood counts, cultures and scans to judge whether the infection is coming under control. Blood counts may show a rise in neutrophils after a transfusion, though the size of that rise varies and can be smaller in people who have developed antibodies against donor white cells. Transfusions cannot continue indefinitely. They usually stop when the infection is controlled, when the person's own neutrophil count recovers, or when the team decides they are not helping. Antibiotic or antifungal treatment continues throughout. Recovery overall depends far more on the underlying illness, the infection and the return of the bone marrow than on the transfusions themselves.
The most important limitation is that it remains unclear how much granulocyte transfusions help. A 2016 Cochrane review of 10 randomized trials in people with neutropenia after chemotherapy or stem cell transplant found too little reliable evidence to tell whether they change survival. The largest modern trial, published in 2015, used donors given G-CSF and dexamethasone and found no overall benefit, but it enrolled only half the planned patients, so it could have missed a real effect. People who received higher doses seemed to do better, a pattern later studies have echoed but not confirmed. Some observational studies, particularly in children, report better survival, but they cannot rule out other explanations. For these reasons, teams usually reserve the treatment for infections that are life-threatening and not responding to other care. The transfusion carries the risks of any blood product: fever and chills, allergic reactions, fluid overload, and destruction of red blood cells if blood types are mismatched. A lung reaction called transfusion-related acute lung injury (TRALI) can be triggered partly by antibodies that react with white cells. Transfusion-associated graft-versus-host disease, in which donor immune cells attack the recipient, is prevented by irradiating the product and has become exceedingly rare since irradiation became routine. Because the cells are given before donor testing is finished, there is also a chance of passing on an infection, such as CMV. Exposure to donor white cells can lead the body to make antibodies against HLA (human leukocyte antigens, the tissue markers used to match transplants). These antibodies can make later granulocyte or platelet transfusions less effective. Transfusions given weeks or months before a planned stem cell transplant can also make it harder to find a matched donor and for the transplant to take, while those given in the days around the transplant itself have not been shown to cause this problem.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with White Blood Cell Transfusion, what to expect, or ask the community a question.